Indazole-carboxamide compounds

A compound of formula (I):

• wherein:
• R1 is hydrogen, halo, hydroxy, C1-4alkyl, or C1-4alkoxy;
• R2 is C3-4alkyl, or C3-6cycloalkyl;
• R3 is hydroxy, C1-3alkoxy, hydroxy-substituted C1-4alkyl, or —OC(O)NRaRb;
• R4 is hydrogen or C1-4alkyl;
• W is selected from (a) Y, wherein Y is selected from —N(R8a)C(O)R9, —N(R8a)S(O)2R10, —N(R8a)C(O)OR12, —N(R8a)C(O)NR13R14, and —N(R8a)S(O)2NR13R14;
• and
• (b) a moiety of formula (b):
• wherein:
• X is selected from —N(R8)C(O)R9, —N(R8)S(O)2R10, —S(R11)O2, —N(R8)C(O)OR12, —N(R8)C(O)NR13R14, —N(R8)S(O)2NR13R14, —C(O)NR13R14, —OC(O)NR13R14, —C(O)OR12, —OR15, —NR8R16, cyano, —SR15, CF3, pyridinyl, pyrrolyl, pyrimidinyl, thiomorpholinyl, thiazolidinyl, 1,1-dioxo isothiazolidinyl, imidazolyl, indolyl, tetrahydrofuranyl, pyrrolidinyl and piperidinyl, wherein pyrrolidinyl is optionally substituted with oxo and piperidinyl is optionally substituted with 1 to 3 halo;
• R5 is hydrogen or C1-4alkyl, wherein C1-4alkyl is optionally substituted with hydroxy, C1-3alkoxy, or cyano;
• R6 and R7 at each occurrence are independently selected from hydrogen, hydroxy, halo, cyano, and C1-4alkyl, wherein C1-4alkyl is optionally substituted with 1 to 2 substituents selected from hydroxy, C1-3alkoxy, halo, and cyano;
• R8 and R8a are hydrogen or C1-4alkyl;
• or R5 and R8, R5 and R6, or R6 and R8 taken together form C2-5alkylenyl, wherein C2-5alkylenyl is optionally substituted with hydroxy, halo, hydroxy-substituted C1-3alkyl, or C1-3alkoxy;
• or R3 and R5 or R3 and R8a taken together form —OCH2CH2—;
• or R5 and R6 taken together form —CH2)q—Q—(CH2)q, wherein Q is oxygen or sulfur and q is independently 0, 1, or 2;
• or R7 and X taken together form —NHC(O)NHC(O)— or —C(O)NHC(O)NH—;
• R9 is selected from hydrogen, furanyl, tetrahydrofuranyl, pyridinyl, or C1-4alkyl, wherein C1-4alkyl is optionally substituted with hydroxy or with from 1 to 3 halo;
• R10 is selected from hydrogen, C1-4alkyl, pyridinyl, and imidazolyl, wherein C1-4alkyl is optionally substituted with —S(O)2Rc, C3-6cycloalkyl, or with from 1 to 3 halo, and imidazolyl is optionally substituted with C1-3alkyl;
• or R8 and R10 taken together form C3alkylenyl;
• R11 is —NRaRb, or C1-4alkyl, where C1-4alkyl is optionally substituted with from 1 to 3 halo;
• or R5 and R11 or R6 and R11 taken together form C2-5alkylenyl;
• R12 is C1-4alkyl;
• R13 and R14 are independently hydrogen or C1-4alkyl;
• R15 is hydrogen or C1-4alkyl, wherein C1-4alkyl is optionally substituted with hydroxy;
• or when X is —SR15, R5 and R15 taken together form C1-4alkylenyl;
• R16 is —CH2)r—R17, wherein r is 0, 1, 2, or 3;
• and R17 is selected from hydrogen, hydroxy, C1-3alkyl, C1-3alkoxy, —C(O)NRaRb, —C(O)-morpholinyl, pyridinyl, pyrrolyl, pyrimidinyl, morpholinyl, and tetrahydrofuranyl, wherein C1-3alkoxy is optionally substituted with hydroxy;
• provided that when r is 0, R17 is selected from hydrogen, C1-3alkyl, pyridinyl, and pyrimidinyl;
• and when r is 1, R17is hydrogen or R17 forms a carbon-carbon bond with the —(CH2)r— carbon atom;
• R18 is —C(O)O—C1-3alkyl, —S(O)2—C1-3alkyl, or —C(O)—C1-3alkyl;
• Ra, Rb, and Rc are independently hydrogen or C1-3alkyl;
• a is 0 or 1;
• and
• n is an integer of 1, 2, 3, 4, or 5;
• provided that when n is 1, X is —SR15, or X forms a carbon-carbon bond with the carbon atom bearing the substituents R6 and R7;
• or a pharmaceutically-acceptable salt or solvate or stereoisomer thereof.